FDA warns AstraZeneca over misleading promotional materials; BMS turns to algorithm as it looks to build heart drug market

Taking stock of the drug industry, from the lab to the medicine chest

August 15, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT+ | FDA warns AstraZeneca over misleading promotional materials for a COPD drug This is only the second letter sent by the FDA's Office of Prescription Drug Promotion to a company this year for a violation. By Ed Silverman STAT+ | SEC wants to know if key supplier of research monkeys bribed foreign officials The SEC is examining whether Inotiv, a key importer of non-human primates for medical research, complied with a federal law. By Ed Silverman STAT+ | BMS, looking to build a market for a heart drug, turns to a Viz.ai algorithm to detect disease As BMS works to build Camzyos into a blockbuster drug, it has propped up a Viz.AI algorithm to detect HCM, the condition it treats. By Mario Aguilar Molly Ferguson for STAT STAT+ | From drug shortages to high prices, U.S. system's shortcomings have deep roots Our system is set up to encourages large drug companies to focus more and more on medicines that can justify an extremely high price. By Matthew Herper Radiation, a mainstay of cancer treatment, begins a fade-out Advances in cancer drugs and surgery mean that doctors can decrease or even omit radiation for more and more cancers. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser